The American drug regulatory has issued the said EIR report with a voluntary action indicated (VAI) status.

The US FDA had conducted an inspection at the company’s manufacturing facility at Pithampur, from 10 August 2026 to 14 August 2026.

Symbiotec Pharmalab is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables.

The company had reported 52.8% fall in consolidated net profit to Rs 14.1 crore despite a 7% rise in revenue from operations to Rs 218.2 crore in Q1 FY27 as compared with Q1 FY26.